ArticleGastroenterology report2026
First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC). Methods: Twenty-one patients with histologically or cytologically confirmed mPC were enrolled in this study. The primary endpoint was progression-free survival (PFS). Meanwhile, the secondary endpoints included the objective response rate (ORR), overall survival, disease control rate (DCR), duration of response (DOR), and safety of combination therapy. Results: The median PFS was 7.4 months (95% confidence interval [CI]: 5.4-9.4 months). The ORR and DCR were 52.4% (95% CI: 29.1%-75.7%) and 95.2% (95% CI: 85.3%-100%), respectively. Amongst patients who achieved partial response, the median DOR was 4.8 months (95% CI: 1.5-8.1 months). No treatment-related deaths were reported. Grade 3-4 adverse events (AEs) occurred in 81.0% of patients, with increased γ-glutamyltransferase levels (38.1%), neutropenia (33.3%), and leukocytopenia (28.6%) being the most frequent AEs. Low SERPINB3 and SERPINB4 expression was correlated with prolonged PFS, accompanied by the significant downregulation of gene sets involved in DNA replication, nonsense-mediated mRNA decay, and protein translation in long-PFS tumours. Tumour immune microenvironment analysis revealed that patients with short PFS had increased levels of common lymphoid progenitors and decreased populations of mature B and T lymphocytes. Conclusions: The combination of pm-Pac and gemcitabine as first-line therapy for mPC exhibited favourable tolerability and clinical efficacy. However, larger randomized-controlled trials are needed to validate these preliminary findings. Trial Registration: www.chictr.org.cn, ChiCTR2300078861.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.